Securities code: 688091 securities abbreviation: Shanghai Yizhong Pharmaceutical Co.Ltd(688091) Announcement No.: 2022-006 Shanghai Yizhong Pharmaceutical Co.Ltd(688091)
Announcement of resolutions of the 8th meeting of the 1st board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of supervisors
The eighth meeting of the first session of the board of supervisors of Shanghai Yizhong Pharmaceutical Co.Ltd(688091) (hereinafter referred to as "the company") was notified in the form of electronic communication on January 30, 2022 and held on site in the Shanghai Yizhong Pharmaceutical Co.Ltd(688091) conference room on February 7, 2022. Three supervisors should attend the meeting and three actually attended. The meeting shall be held in accordance with laws and regulations, the company law and the articles of association. The resolutions of the meeting are legal and effective.
The meeting was presided over by Ms. pan ruogan, chairman of the board of supervisors. After careful deliberation and voting, all supervisors attending the meeting formed the following resolutions:
2、 Deliberation at the meeting of the board of supervisors
(I) the proposal on adjusting the construction content of the raised investment project with an annual output of 5 million paclitaxel polymer micelles for injection and supporting facilities was reviewed and approved
The board of supervisors believes that the construction content of the raised investment project of the company's adjustment to the construction of 5 million paclitaxel polymer micelles and supporting facilities for injection this time is based on the actual needs of the current raised investment project construction, meets the purpose of the raised funds, and has fulfilled the necessary procedures. It complies with the relevant provisions of the guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the application of self regulatory rules for listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 - standardized operation, and the company's raised funds management system, and there is no damage to the interests of the company and shareholders. The board of supervisors agreed to the proposal on adjusting the construction content of the raised investment project with an annual output of 5 million paclitaxel polymer micelles and supporting facilities for injection.
Voting: 3 in favor, 0 against and 0 abstention.
(II) the proposal on the adjustment of the amount of raised funds to be invested between different implementation entities of the project with an annual output of 5 million paclitaxel polymer micelles for injection and the construction of supporting facilities was reviewed and approved
The board of supervisors believes that the adjustment of the proposed investment amount of the raised funds among different implementation entities of the project is based on the actual needs of the project construction, which is conducive to ensuring the efficient implementation of the project, improving the use efficiency of the raised funds, and fulfilling the necessary procedures, It complies with the relevant provisions of the guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the application of self regulatory rules for listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 - standardized operation, and the company's raised funds management system, and there is no damage to the interests of the company and shareholders. The board of supervisors agreed to the proposal on the adjustment of the amount of raised funds to be invested between different implementation entities of the project with an annual output of 5 million paclitaxel polymer micelles for injection and the construction of supporting facilities.
Voting: 3 in favor, 0 against and 0 abstention.
It is hereby announced.
Shanghai Yizhong Pharmaceutical Co.Ltd(688091) board of supervisors February 9, 2022